Outcomes following general anaesthesia in children with hypertrophic cardiomyopathy

Gabrielle Norrish1,2, Natalie Forshaw3, Colleen Woo3

  • 1Centre for Inherited Cardiovascular Diseases, Great Ormond Street Hospital, London, UK.

Insights

Children with hypertrophic cardiomyopathy (HCM) can undergo general anaesthesia (GA) with low risk. This study found a low prevalence of complications and mortality in pediatric patients receiving GA for HCM.

Area of Science:

  • Cardiology
  • Anesthesiology
  • Pediatrics

Background:

  • Hypertrophic cardiomyopathy (HCM) in children has historically been associated with high-risk general anaesthesia (GA).
  • Limited evidence exists on the safety and perioperative outcomes of GA in pediatric HCM patients.

Purpose of the Study:

  • To evaluate the safety and perioperative outcomes of general anaesthesia (GA) in pediatric patients with hypertrophic cardiomyopathy (HCM).

Main Methods:

  • A retrospective review of clinical features and outcomes for pediatric patients (<18 years) with HCM undergoing GA between 2000 and 2016.
  • Analysis of patient demographics, HCM aetiology, echocardiographic parameters (mean maximal wall thickness, left ventricular outflow tract gradient), and perioperative complications.

Main Results:

  • 86 pediatric patients underwent 164 GA procedures; common aetiologies included non-syndromic disease (56%) and malformation syndromes (26%).
  • Mean maximal wall thickness was 19 mm; 14% had severe left ventricular hypertrophy and 21% had significant left ventricular outflow tract gradients.
  • The majority (87%) experienced no perioperative complications, with minor complications (bradycardia, hypotension) in 12%. One patient (0.6%) experienced cardiac arrest and subsequent death.

Conclusions:

  • General anaesthesia (GA) in pediatric patients with hypertrophic cardiomyopathy (HCM) can be performed with relatively low perianaesthetic mortality (0.6%) and minor complication rates (12%) in expert centers.
  • Clinical parameters like age, wall thickness, or outflow tract gradients did not predict increased anesthetic risk.
  • Further research is needed to identify specific clinical features that may predict anesthetic risk in this population.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
490
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
568
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
538
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
442
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
605
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
356